Management of Neovascular Age-Related Macular Degeneration: Improving Patient Outcomes
Neovascular age-related macular degeneration (nAMD) is the leading cause of vision loss and blindness in older Americans. While there are multiple anti-VEGF agents for nAMD, real-world outcomes are significantly lower than those demonstrated in clinical trials. In order to help overcome this discrepancy, ophthalmologists should be kept up to date regarding the most recent approvals and related trial data, as well as being given strategies and tools to overcome patients’ lack of adherence to anti-VEGF therapies.
The intended audience for this initiative is ophthalmologists involved in the management of adults with nAMD.
At the conclusion of this activity, participants should be able to:
- Evaluate the latest clinical trial data for the agents currently approved, used off-label, and in development for nAMD
- Incorporate available approved and off-label treatments into precision-based nAMD management plans
- Indicate strategies to encourage adherence to anti-VEGF treatment in patients with nAMD
This program is supported by an educational grant from Novartis.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Rockpointe. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
- 1.00 AMA PRA Category 1 Credit™Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Boston University School of Medicine designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.